Field Therapy in Solid Organ Transplant Recipients: Are We Initiating Early Enough?
March 2020 | Volume 19 | Issue 3 | Editorials | 335 | Copyright © March 2020
Published online February 21, 2020
Christina Topham , Dylan Haynes , R. Samuel Hopkins , Justin Leitenberger
Oregon Health & Science University, Portland, OR
Organ transplant recipients (OTRs) are at increased risk for more aggressive non-melanoma skin cancer (NMSC). Recent emphasis on field therapy has complimented the canonical surgical treatment paradigm. This retrospective analysis of survey responses by patients seen at Oregon Health and Science University from 2013-2018 offers insights into patient trends and practice gaps in caring for OTRs. All patients completed a 57-point questionnaire at their first clinic visit, which included questions regarding demographics, transplant history, dermatologic history, and use of field therapy. Of the 295 patients (mean age, 56 years; M/F: 193/102) who completed the questionnaire, field therapy was reported by 31 (11%) patients. Field therapy patients noted an overall higher AK and SCC burden, with a greater proportion of patients reporting >20 AKs and >10 SCCs. Field therapy use was sparse in the low AK/low SCC group (n=25) when compared to those reporting high AK/high SCC (n=11) burden (n=4 (16%) vs n=8 (73%), P<0.01). This data suggests that OTRs with several clinically evident AKs and/or a low number of SCCs are less likely to have been treated with field therapy modalities compared to OTRs who have developed >10 AKs or ≥6 SCCs. A delay in initiation of preventative measures or field therapy in this population, however, may be a missed opportunity for intervention. Early intervention with field therapy in particularly high-risk OTRs with a low skin cancer burden may mitigate future skin cancer development.J Drugs Dermatol. 2020;19(3): doi:10.36849/JDD.2020.4759
Organ transplant recipients (OTRs) are at increased risk for skin cancer, especially non-melanoma skin cancer (NMSC). In OTRs, NMSC tends to be more aggressive and result in higher rates of local recurrence and metastases.1 Furthermore, areas of high (pre-)malignant burden, or “field cancerization,” are common in this population.1 Recent emphasis on “field therapy,” or topical immunomodulatory regimens levied against field cancerization, has complimented the canonical surgical treatment paradigm.2 We highlight survey data of a single-center specialty clinic noting a practice-gap in early initiation of field therapy in immunosuppressed patients.
This retrospective cohort included all OTRs seen in a high-risk, post-transplant NMSC clinic in the Department of Dermatology at Oregon Health and Science University (OHSU) from 2013 to 2018. All patients completed a 57-point questionnaire at their first clinic visit, which included questions regarding demographics, transplant history, dermatologic history, and use of field therapy. Survey responses were entered into the Research Electronic Data Capture application. Data analysis was performed in the STATA statistical analysis program, version 15. Inferential statistics were performed using McNemar’s and two-sample tests of proportion. The institutional review board at OHSU approved this study.
In total, 295 patients completed the questionnaire. Mean respondent age was 56 ± 15 years and 193 (65%) were men (Table 1). Field therapy was reported by 31 (11%) patients. Of those patients, 18 (58%) noted some improvement from the field therapy and four (13%) experienced an adverse effect as a result of field therapy. Actinic keratosis (AK) burden survey categories were defined as <5, 5-10, 11-20, >20, and unknown. Squamous cell carcinoma (SCC) burden survey categories were defined as 1, 2-5, 6-10, >10, and unknown. Field therapy patients noted an overall higher AK and SCC burden, with a greater proportion of patients reporting >20 AKs and >10 SCCs (Table 2).
Mid-range survey categories were used to define post-hoc cutoffs for low and high skin cancer burden for both AKs and SCCs. Low burden was defined as ≤10 AKs and <6 SCCs, whereas high skin cancer burden was defined as >10 AKs and ≥6 SCCs. Twenty-five patients reported a low AK/low SCC burden, and 11 reported a high AK/high SCC burden post-transplant. Field therapy use was sparse in the low AK/low SCC group when compared to those reporting high AK/high SCC burden (n=4 (16%) vs n=8 (73%); P<0.01) (Table 2).